Obizur Approved for Acquired Hemophilia A
October 23, 2014 – Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] was approved by the US Food and Drug Administration (FDA) for the treatment of bleeding episodes in adult patients with acquired hemophilia A, a rare and potentially life-threatening acute bleeding disorder. Obizur is not indicated for the treatment of congenital hemophilia A or von Willebrand Disease.
The manufacturer of Obizur is Baxter Pharmaceuticals. Obizur is administered through an intravenous infusion and Baxter is expected to begin distribution to hospitals during the first quarter of 2015.
If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.